Whalesbook
Indian Drugmakers Launch Generic Semaglutide
The expiry of Novo Nordisk's patent on semaglutide on March 20 has prompted an immediate wave of launches from Indian pharmaceutical firms. Sun Pharma, Torrent Pharmaceuticals, Dr Reddy's Laboratories, Glenmark Pharmaceuticals, and Alkem Laboratories have launched their semaglutide formulations, promising significant price cuts for patients. This move aims to capture a large share of India's growing market for metabolic disorder treatments.
Prices Plummet, Making Treatment Affordable
Sun Pharma's weekly therapy, under brands like Noveltreat and Sematrinity, will range from approximately ₹750 to ₹2,000, a sharp contrast to the premium pricing of innovator drugs. Kirti Ganorkar, managing director at Sun Pharma, highlighted the launch of a patient support program designed to guide individuals throughout their treatment journey. Torrent Pharma is distinguishing itself by offering both oral and injectable versions, providing healthcare professionals with comprehensive options for managing type-2 diabetes and obesity. Amal Kelshikar, CEO of Torrent Pharma's India Business, expressed pride in being the first Indian company to provide this dual-formulation approach.
Meeting India's Rising Diabetes and Obesity Needs
These launches come as India faces a significant public health challenge: rising diabetes rates, affecting over 100 million people. Global blockbusters like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, while recently introduced in India, command higher prices. Semaglutide, a drug that mimics a hormone to improve blood sugar control, promote fullness, and curb food cravings, helps patients lose weight. These cheaper, domestically produced alternatives are expected to dramatically increase patient access to these life-changing therapies and shift the competitive landscape in the Indian pharmaceutical sector.